BRISTOL-MYERS SQUIBB MERGER: GELB AND FURLAUD's LEGACY WILL BE $ 8.6 BIL. COMBO WITH STRATEGIC FIT, CRITICAL MASS, OTCs, AND SUSTAINABLE R&D PIPELINE

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".